Trinity Biosystems raises $7.5M bridge to treat endocrine disorders
Trinity Biosystems, maker of a drug that can treat certain endocrine disorders, has brought in $7.5 million in bridge funding from Amgen Ventures, Life Science Partners, Lilly Ventures, Sanderling Ventures and SR One, according to Dow Jones VentureWire. Based in Menlo Park, Calif., the company has raised about $33.75 million since its first round of financing in 2004.
Life-science briefing: Friday, March 14, 2008
TODAY’S HEADLINES
Cantimer takes in $2M for dehydration diagnostics (VentureWire)
Recodagen launches, takes aim at cancer (release)
Juniper Diagnostics spins out of ChemSensing (VentureWire)
Cantimer takes in $2M for dehydration diagnostics –The mystery of Menlo Park, Calif.-based Cantimer has resolved a bit. We wrote about this stealthy company back in December and reached the conclusion that the company was developing a particular type of nanosensor intended to identify water levels in human tissue.
Now VentureWire reports that Cantimer is doing… Continue Reading
Life sciences briefing: Friday, Oct. 26, 2007
Featured companies: Allozyne, Arteriocyte Medical Systems, Arthrosurface, Bay City Capital, EnteroMedics, OncoVista, Novotech, Power Medical Interventions, Reliant Technologies
UPDATED: Expanded items on Allozyne, Reliant Tech, Power Medical and Bay City Capital.
UPDATE REDUX: Added item on EnteroMedics IPO.
Seattle’s Allozyne draws $30M for new interferon — Allozyne, a Seattle biotech focused on tweaking existing protein-based drugs to improve their properties, raised $30 million in a second round of financing. Investors included MPM Capital, OVP Venture Partners, Amgen Ventures, ARCH Venture… Continue Reading
Argolyn draws on $16M for neurological drugs
Argolyn Bioscience, a Charleston, S.C.-based developer of drugs for neurological problems, raised $15.8 million in a first financing round. The funding was led by Intersouth Partners and Quaker BioVentures, joined by Amgen Ventures.
Argolyn is at work on new peptide-based drugs, which are made from short stretches of protein, for schizophrenia and pain. Neither of its lead candidates have yet entered clinical trials, although the company said the new funding will allow it to begin human… Continue Reading